Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xla1 in Healthy Volunteers and Overweight/Obese Adults
NCT04663139Phase 1Completed
- Sponsor
- YSOPIA Bioscience
- Start
- Nov 2020
- Primary completion
- Jun 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Xla1 in obesity (3 arms), sponsored by YSOPIA Bioscience. Primary endpoint: Number of patients experiencing adverse events at 12 weeks. Started Nov 2020; status: completed.
02
Drugs
Xla1
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04663139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04663139.